每个月,处方集专著服务的订户将收到5至6本记录良好的专著，这些专著涉及新发布或处于第三阶段后期试验中的药物。专着针对药房和治疗委员会。订户还每月收到1页的关于代理商的摘要专著，这些专著对议程和药房/护理服务很有用。每月还提供全面的目标药物利用评估/药物使用评估（DUE/MUE）。有了订阅，专著可在线获得订户。专着可以定制以满足设施的需求。通过《处方集》的合作，医院药房在此专栏中发布选定的评论。有关处方集专著服务的更多信息，致电866-397-3433与WoltersKluwer客户服务部联系。2017年11月的专著主题是Ertugliflozin，Glecaprevir/pibrentasvir,Neratinib,Sofosbuvir,velpatasvir,voxilaprevir和SQC1酯酶抑制剂。MUE在glecaprevir上，pibrentasvir.
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The November 2017 monograph topics are Ertugliflozin, Glecaprevir / pibrentasvir, Neratinib, Sofosbuvir, velpatasvir, voxilaprevir and SQ C1 esterase inhibitor. The MUE is on glecaprevir, pibrentasvir.
PDF(Sci-hub)